Physician profile
Manuel Perez
NPI 1225611221
$476.52
in general payments reported to CMS, 2019-2025
12 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.87 · 2024: $226 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $105.61 | 2024-2025 | Fruzaqla, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $90.18 | 2024-2025 | Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $58.92 | 2025 | Datroway, Enhertu |
| Regeneron Healthcare Solutions, INC. | $44.14 | 2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $33.99 | 2025 | Opdivo |
| Janssen Biotech, INC. | $27.78 | 2024 | Erleada, Rybrevant, Akeega |
| Gilead Sciences, INC. | $23.54 | 2025 | Trodelvy |
| Eisai INC. | $20.61 | 2025 | |
| Adaptive Biotechnologies Corporation | $18.87 | 2023 | Clonoseq |
| Lilly USA, LLC | $18.09 | 2024 | Retevmo |
| Sumitomo Pharma America, INC. | $17.53 | 2024 | Gemtesa |
| Incyte Corporation | $17.26 | 2025 | Niktimvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.